vs
ARTIVION, INC.（AORT）とMERIT MEDICAL SYSTEMS INC（MMSI）の財務データ比較。上の社名をクリックして会社を切り替えられます
MERIT MEDICAL SYSTEMS INCの直近四半期売上が大きい（$393.9M vs $116.0M、ARTIVION, INC.の約3.4倍）。MERIT MEDICAL SYSTEMS INCの純利益率が高く（9.6% vs 2.1%、差は7.6%）。ARTIVION, INC.の前年同期比売上増加率が高い（19.2% vs 10.9%）。MERIT MEDICAL SYSTEMS INCの直近四半期フリーキャッシュフローが多い（$74.0M vs $-7.9M）。過去8四半期でMERIT MEDICAL SYSTEMS INCの売上複合成長率が高い（10.3% vs 9.1%）
Artivion, Inc.は心血管移植向けの極低温保存した人体組織の流通、及び医療機器の開発を行う医療企業です。同社の製品には、余分な細胞物質と抗原を除去する処理を施した人間の心臓弁、手術用接着剤BioGlueなどがあり、臨床現場のニーズに応えています。
メリットメディカルシステムズ社はグローバルな医療機器メーカーで、心臓病学、放射線学、腫瘍学、内視鏡検査、救命救護の各分野で使用される介入・診断用製品を開発・製造・販売しています。世界中の病院や医療機関に低侵襲のソリューションを提供し、患者の予後改善と診療効率の向上を支援しています。
AORT vs MMSI — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $116.0M | $393.9M |
| 純利益 | $2.4M | $38.0M |
| 粗利率 | 63.1% | 49.6% |
| 営業利益率 | 9.2% | 13.8% |
| 純利益率 | 2.1% | 9.6% |
| 売上前年比 | 19.2% | 10.9% |
| 純利益前年比 | 114.7% | 36.0% |
| EPS（希薄化後） | $0.06 | $0.64 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $116.0M | $393.9M | ||
| Q3 25 | $113.4M | $384.2M | ||
| Q2 25 | $113.0M | $382.5M | ||
| Q1 25 | $99.0M | $355.4M | ||
| Q4 24 | $97.3M | $355.2M | ||
| Q3 24 | $95.8M | $339.8M | ||
| Q2 24 | $98.0M | $338.0M | ||
| Q1 24 | $97.4M | $323.5M |
| Q4 25 | $2.4M | $38.0M | ||
| Q3 25 | $6.5M | $27.8M | ||
| Q2 25 | $1.3M | $32.6M | ||
| Q1 25 | $-505.0K | $30.1M | ||
| Q4 24 | $-16.5M | $27.9M | ||
| Q3 24 | $-2.3M | $28.4M | ||
| Q2 24 | $-2.1M | $35.7M | ||
| Q1 24 | $7.5M | $28.2M |
| Q4 25 | 63.1% | 49.6% | ||
| Q3 25 | 65.6% | 48.5% | ||
| Q2 25 | 64.7% | 48.2% | ||
| Q1 25 | 64.2% | 48.4% | ||
| Q4 24 | 63.2% | 48.7% | ||
| Q3 24 | 63.7% | 46.4% | ||
| Q2 24 | 64.6% | 47.7% | ||
| Q1 24 | 64.6% | 46.9% |
| Q4 25 | 9.2% | 13.8% | ||
| Q3 25 | 11.1% | 11.1% | ||
| Q2 25 | 7.4% | 12.3% | ||
| Q1 25 | 2.2% | 11.5% | ||
| Q4 24 | 2.7% | 10.3% | ||
| Q3 24 | 4.6% | 11.0% | ||
| Q2 24 | 6.6% | 13.6% | ||
| Q1 24 | 26.0% | 11.1% |
| Q4 25 | 2.1% | 9.6% | ||
| Q3 25 | 5.7% | 7.2% | ||
| Q2 25 | 1.2% | 8.5% | ||
| Q1 25 | -0.5% | 8.5% | ||
| Q4 24 | -16.9% | 7.9% | ||
| Q3 24 | -2.4% | 8.4% | ||
| Q2 24 | -2.2% | 10.6% | ||
| Q1 24 | 7.7% | 8.7% |
| Q4 25 | $0.06 | $0.64 | ||
| Q3 25 | $0.13 | $0.46 | ||
| Q2 25 | $0.03 | $0.54 | ||
| Q1 25 | $-0.01 | $0.49 | ||
| Q4 24 | $-0.40 | $0.46 | ||
| Q3 24 | $-0.05 | $0.48 | ||
| Q2 24 | $-0.05 | $0.61 | ||
| Q1 24 | $0.18 | $0.48 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $64.9M | $446.4M |
| 総負債低いほど良い | $215.1M | $734.0M |
| 株主資本純資産 | $448.2M | $1.6B |
| 総資産 | $884.8M | $2.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.48× | 0.46× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $64.9M | $446.4M | ||
| Q3 25 | $73.4M | $392.5M | ||
| Q2 25 | $53.5M | $341.8M | ||
| Q1 25 | $37.7M | $395.5M | ||
| Q4 24 | $53.5M | $376.7M | ||
| Q3 24 | $56.2M | $523.1M | ||
| Q2 24 | $55.0M | $636.7M | ||
| Q1 24 | $51.1M | $581.9M |
| Q4 25 | $215.1M | $734.0M | ||
| Q3 25 | $214.9M | $732.9M | ||
| Q2 25 | $215.6M | $731.8M | ||
| Q1 25 | $314.7M | $730.7M | ||
| Q4 24 | $314.3M | $729.6M | ||
| Q3 24 | $314.0M | $750.5M | ||
| Q2 24 | $313.6M | $801.3M | ||
| Q1 24 | $313.3M | $800.1M |
| Q4 25 | $448.2M | $1.6B | ||
| Q3 25 | $438.7M | $1.5B | ||
| Q2 25 | $419.9M | $1.5B | ||
| Q1 25 | $294.3M | $1.4B | ||
| Q4 24 | $276.2M | $1.4B | ||
| Q3 24 | $304.7M | $1.3B | ||
| Q2 24 | $295.1M | $1.3B | ||
| Q1 24 | $295.0M | $1.2B |
| Q4 25 | $884.8M | $2.7B | ||
| Q3 25 | $857.7M | $2.6B | ||
| Q2 25 | $838.4M | $2.6B | ||
| Q1 25 | $791.2M | $2.5B | ||
| Q4 24 | $789.1M | $2.4B | ||
| Q3 24 | $803.1M | $2.4B | ||
| Q2 24 | $789.5M | $2.4B | ||
| Q1 24 | $784.0M | $2.3B |
| Q4 25 | 0.48× | 0.46× | ||
| Q3 25 | 0.49× | 0.48× | ||
| Q2 25 | 0.51× | 0.49× | ||
| Q1 25 | 1.07× | 0.51× | ||
| Q4 24 | 1.14× | 0.53× | ||
| Q3 24 | 1.03× | 0.57× | ||
| Q2 24 | 1.06× | 0.62× | ||
| Q1 24 | 1.06× | 0.65× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.6M | $98.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $-7.9M | $74.0M |
| FCFマージンFCF / 売上 | -6.9% | 18.8% |
| 設備投資強度設備投資 / 売上 | 23.7% | 6.2% |
| キャッシュ転換率営業CF / 純利益 | 8.06× | 2.59× |
| 直近12ヶ月FCF直近4四半期 | $839.0K | $215.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.6M | $98.5M | ||
| Q3 25 | $22.3M | $75.0M | ||
| Q2 25 | $15.0M | $83.3M | ||
| Q1 25 | $-17.0M | $40.6M | ||
| Q4 24 | $10.1M | $68.7M | ||
| Q3 24 | $11.5M | $47.3M | ||
| Q2 24 | $6.1M | $68.5M | ||
| Q1 24 | $-5.5M | $36.2M |
| Q4 25 | $-7.9M | $74.0M | ||
| Q3 25 | $17.7M | $52.5M | ||
| Q2 25 | $11.7M | $69.6M | ||
| Q1 25 | $-20.6M | $19.5M | ||
| Q4 24 | $8.7M | $65.3M | ||
| Q3 24 | $7.8M | $38.0M | ||
| Q2 24 | $3.6M | $57.9M | ||
| Q1 24 | $-9.1M | $24.5M |
| Q4 25 | -6.9% | 18.8% | ||
| Q3 25 | 15.6% | 13.7% | ||
| Q2 25 | 10.4% | 18.2% | ||
| Q1 25 | -20.8% | 5.5% | ||
| Q4 24 | 9.0% | 18.4% | ||
| Q3 24 | 8.2% | 11.2% | ||
| Q2 24 | 3.7% | 17.1% | ||
| Q1 24 | -9.3% | 7.6% |
| Q4 25 | 23.7% | 6.2% | ||
| Q3 25 | 4.1% | 5.8% | ||
| Q2 25 | 2.9% | 3.6% | ||
| Q1 25 | 3.7% | 5.9% | ||
| Q4 24 | 1.5% | 1.0% | ||
| Q3 24 | 3.8% | 2.8% | ||
| Q2 24 | 2.6% | 3.1% | ||
| Q1 24 | 3.7% | 3.6% |
| Q4 25 | 8.06× | 2.59× | ||
| Q3 25 | 3.42× | 2.70× | ||
| Q2 25 | 11.16× | 2.56× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.92× | ||
| Q1 24 | -0.73× | 1.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
